Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study
European Journal of Internal Medicine · 2025
DOI: 10.1016/j.ejim.2025.06.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Internal Medicine, 2025. Verfasst von Alicia Trenas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND.…. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Department of Internal Medicine, University of Utah, European Regional Development Fund.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: There is limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. This work analyzes the efficacy of once-daily oral semaglutide in terms of health status and change in body weight in patients with heart failure with preserved ejection fraction, type 2 diabetes, and obesity. METHODS: This prospective, real-world study included patients treated with once-daily semaglutide (O-Sema Group) and without glucagon-like peptide-1 receptor agonists (Control Group). The primary outcome was the heart failure status, defined as the ≥5 point difference in the Kansas City Cardiomyopathy Questionnaire total symptom score, and change in body weight at 18 months. RESULTS: After a 1:1 propensity score matching, 202 patients were included in each group (mean age 77.8 years, mean body mass index 33.5, 59.2 % females). Patients in the O-Sema Group were more likely to have an improvement in heart failure health status from baseline to 18 months (OR:2.92; 95 %CI: 1.45-4.90; p < 0.01). The mean change in body weight was -9.5 ± 3.2 kg in patients with oral semaglutide and -2.0 ± 1.1 kg in control patients (p < 0.01). After treatment, there were negative correlations between the Kansas City Cardiomyopathy Questionnaire total symptom score and the body weight (r=-0.577, p < 0.01) and glycated hemoglobin (r=-0.499, p = 0.011). It had good tolerability and safety. CONCLUSIONS: Once-daily oral semaglutide was associated with an improvement in heart failure health status, and weight loss in patients with heart failure with preserved ejection fraction, type 2 diabetes, and obesity. Further research on glucagon-like peptide-1 receptor agonists in heart failure with preserved ejection fraction is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND. Universidad de Málaga, Málaga, Spain.
- Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND. Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédi…
- Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
- Servicio de Nefrología, Hospital Regional Universitario de Málaga, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, RICORS2040 (RD21/0005/0012 and RD24/0004/0026), Mála…
- Departamento de Medicina y Dermatología, Facultad de Medicina, Universidad de Málaga (UMA), Instituto de Investigación Biomédica de Málaga (IBIMA) - Plataforma BIONAND, Málaga, Spain.
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Endocrinología y Nutrición. Hospital Universitario Virgen de la Vi…
Förderung
- Department of Internal Medicine, University of Utah
- European Regional Development Fund
Zitieren
APA
Trenas, A., Pérez-Velasco, M. A., Bernal-López, M. R., López-Carmona, M. D., Gómez-Doblas, J. J., Martínez-Esteban, M. D., Bouarich, O., García-Casares, N., Fernández-García, D., de Lucas, M. G., Gómez-Huelgas, R., & Pérez-Belmonte, L. M. (2025). Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2025.06.007
Vancouver
Trenas A, Pérez-Velasco MA, Bernal-López MR, López-Carmona MD, Gómez-Doblas JJ, Martínez-Esteban MD, et al. Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study. European Journal of Internal Medicine. 2025. doi:10.1016/j.ejim.2025.06.007
BibTeX
@article{Trenas2025,
author = {Trenas, Alicia and Pérez-Velasco, Miguel A and Bernal-López, Maria-Rosa and López-Carmona, María-Dolores and Gómez-Doblas, Juan J and Martínez-Esteban, María-Dolores and Bouarich, Oumayma and García-Casares, Natalia and Fernández-García, Diego and de Lucas, María-Dolores García and Gómez-Huelgas, Ricardo and Pérez-Belmonte, Luis M},
title = {Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study},
journal = {European Journal of Internal Medicine},
year = {2025},
doi = {10.1016/j.ejim.2025.06.007}
}
EUVIMED